We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why the Market Dipped But Hologic (HOLX) Gained Today
Read MoreHide Full Article
Hologic (HOLX - Free Report) closed at $68.50 in the latest trading session, marking a +2.24% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.63%. Elsewhere, the Dow lost 0.65%, while the tech-heavy Nasdaq lost 0.47%.
The medical device maker's shares have seen a decrease of 1.76% over the last month, not keeping up with the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92%.
The upcoming earnings release of Hologic will be of great interest to investors. The company's earnings report is expected on November 3, 2025. On that day, Hologic is projected to report earnings of $1.1 per share, which would represent year-over-year growth of 8.91%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.03 billion, up 4.67% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $4.24 per share and revenue of $4.08 billion. These totals would mark changes of +3.92% and 0%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Hologic. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.11% decrease. Hologic is holding a Zacks Rank of #4 (Sell) right now.
Digging into valuation, Hologic currently has a Forward P/E ratio of 14.96. This expresses a discount compared to the average Forward P/E of 23.97 of its industry.
It's also important to note that HOLX currently trades at a PEG ratio of 2.3. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Instruments industry currently had an average PEG ratio of 2.54 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 89, putting it in the top 37% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why the Market Dipped But Hologic (HOLX) Gained Today
Hologic (HOLX - Free Report) closed at $68.50 in the latest trading session, marking a +2.24% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.63%. Elsewhere, the Dow lost 0.65%, while the tech-heavy Nasdaq lost 0.47%.
The medical device maker's shares have seen a decrease of 1.76% over the last month, not keeping up with the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92%.
The upcoming earnings release of Hologic will be of great interest to investors. The company's earnings report is expected on November 3, 2025. On that day, Hologic is projected to report earnings of $1.1 per share, which would represent year-over-year growth of 8.91%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.03 billion, up 4.67% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $4.24 per share and revenue of $4.08 billion. These totals would mark changes of +3.92% and 0%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Hologic. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.11% decrease. Hologic is holding a Zacks Rank of #4 (Sell) right now.
Digging into valuation, Hologic currently has a Forward P/E ratio of 14.96. This expresses a discount compared to the average Forward P/E of 23.97 of its industry.
It's also important to note that HOLX currently trades at a PEG ratio of 2.3. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Instruments industry currently had an average PEG ratio of 2.54 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 89, putting it in the top 37% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.